These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 9867311)
1. Design and delivery of non-parenteral vaccines. Nugent J; Po AL; Scott EM J Clin Pharm Ther; 1998 Aug; 23(4):257-85. PubMed ID: 9867311 [TBL] [Abstract][Full Text] [Related]
2. Mucosal delivery of vaccine antigens and its advantages in pediatrics. De Magistris MT Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335 [TBL] [Abstract][Full Text] [Related]
3. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria. van Roosmalen ML; Kanninga R; El Khattabi M; Neef J; Audouy S; Bosma T; Kuipers A; Post E; Steen A; Kok J; Buist G; Kuipers OP; Robillard G; Leenhouts K Methods; 2006 Feb; 38(2):144-9. PubMed ID: 16414272 [TBL] [Abstract][Full Text] [Related]
4. DNA vaccines--challenges in delivery. Pachuk CJ; McCallus DE; Weiner DB; Satishchandran C Curr Opin Mol Ther; 2000 Apr; 2(2):188-98. PubMed ID: 11249641 [TBL] [Abstract][Full Text] [Related]
5. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762 [TBL] [Abstract][Full Text] [Related]
6. Immunity in response to particulate antigen-delivery systems. Storni T; Kündig TM; Senti G; Johansen P Adv Drug Deliv Rev; 2005 Jan; 57(3):333-55. PubMed ID: 15560945 [TBL] [Abstract][Full Text] [Related]
7. New generation of mucosal adjuvants for the induction of protective immunity. Yuki Y; Kiyono H Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340 [TBL] [Abstract][Full Text] [Related]
8. Mucosal delivery of vaccines in domestic animals. Gerdts V; Mutwiri GK; Tikoo SK; Babiuk LA Vet Res; 2006; 37(3):487-510. PubMed ID: 16611560 [TBL] [Abstract][Full Text] [Related]
15. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556 [TBL] [Abstract][Full Text] [Related]
16. Adjuvants and delivery systems for viral vaccines--mechanisms and potential. Jennings R; Simms JR; Heath AW Dev Biol Stand; 1998; 92():19-28. PubMed ID: 9554256 [TBL] [Abstract][Full Text] [Related]
17. Delivery systems: a vaccine strategy for overcoming mucosal tolerance? Mann JF; Acevedo R; Campo JD; Pérez O; Ferro VA Expert Rev Vaccines; 2009 Jan; 8(1):103-12. PubMed ID: 19093777 [TBL] [Abstract][Full Text] [Related]
18. Heterologous protein production and delivery systems for Lactococcus lactis. Nouaille S; Ribeiro LA; Miyoshi A; Pontes D; Le Loir Y; Oliveira SC; Langella P; Azevedo V Genet Mol Res; 2003 Mar; 2(1):102-11. PubMed ID: 12917806 [TBL] [Abstract][Full Text] [Related]
19. Vaccine candidates in STD. Fletcher MA Int J STD AIDS; 2002 Dec; 13 Suppl 2():38-41. PubMed ID: 12537725 [TBL] [Abstract][Full Text] [Related]
20. Live bacterial delivery systems for development of mucosal vaccines. Thole JE; van Dalen PJ; Havenith CE; Pouwels PH; Seegers JF; Tielen FD; van der Zee MD; Zegers ND; Shaw M Curr Opin Mol Ther; 2000 Feb; 2(1):94-9. PubMed ID: 11249657 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]